HT-001, HT-001, The corresponding placebo is formulated using the same excipients as HT-001 and is identical in color and physical appearance., HT-001
CLEER-001
Phase 2 small_molecule active
Quick answer
HT-001, HT-001, The corresponding placebo is formulated using the same excipients as HT-001 and is identical in color and physical appearance., HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors is a Phase 2 program (small_molecule) at Hoth Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoth Therapeutics
- Indication
- Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active